Raymond James Maintains Strong Buy on DexCom, Raises Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Jayson Bedford has maintained a Strong Buy rating on DexCom (NASDAQ:DXCM) and increased the price target from $151 to $160.
April 26, 2024 | 5:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Raymond James has reaffirmed its Strong Buy rating on DexCom and raised the price target from $151 to $160.
The upgrade in price target by a reputable analyst like Jayson Bedford from Raymond James is a strong positive signal for DexCom. It suggests confidence in the company's future performance and growth potential, likely leading to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100